Disc MedicineIRON
IRON
About: Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
Employees: 78
0
Funds holding %
of 7,290 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
147% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 15
65% more call options, than puts
Call options by funds: $3.7M | Put options by funds: $2.24M
25% more capital invested
Capital invested by funds: $1.35B [Q3] → $1.68B (+$333M) [Q4]
14% more funds holding
Funds holding: 132 [Q3] → 151 (+19) [Q4]
14% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]
9% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 45
3.11% less ownership
Funds ownership: 92.41% [Q3] → 89.3% (-3.11%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$73
37%
upside
Avg. target
$95
78%
upside
High target
$118
121%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Stifel Benjamin Burnett 40% 1-year accuracy 6 / 15 met price target | 76%upside $94 | Buy Maintained | 24 Jan 2025 |
Scotiabank Greg Harrison 45% 1-year accuracy 15 / 33 met price target | 37%upside $73 | Sector Outperform Maintained | 22 Jan 2025 |
HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 60 / 184 met price target | 121%upside $118 | Buy Reiterated | 21 Jan 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
1 month ago
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of its upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Disc is selling 3,918,182 shares of common stock and pre-funded warrants to purchase 181,818 shares of common stock in the offering. The shares of common stock are being sold at an offering price of $55.00 per share, and the pre-funded warrants are being sold at an offering price of $54.9999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Disc from this offering are expected to be approximately $225.5 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional $33.825 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities being sold in the offering are being offered by Disc. The offering is expected to close on January 24, 2025, subject to the satisfaction of customary closing conditions.
Negative
Benzinga
1 month ago
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Wednesday.
Neutral
GlobeNewsWire
1 month ago
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has commenced an underwritten offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Disc intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities being sold in the proposed offering are being offered by Disc. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
1 month ago
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission
WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the APOLLO post-marketing confirmatory trial for bitopertin in EPP.
Neutral
GlobeNewsWire
1 month ago
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST.
Neutral
GlobeNewsWire
1 month ago
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
WATERTOWN, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the grant of an inducement equity award to a new employee, effective January 16, 2025.
Neutral
GlobeNewsWire
2 months ago
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ASH 2024 annual meeting in San Diego, CA. This year's presentations included updates from the BEACON and AURORA trials of bitopertin in patients with erythropoietic protoporphyria (EPP) and the Phase 1 SAD/MAD trial of DISC-3405 in healthy volunteers. Additionally, Disc presented a real-world patient survey highlighting the disease burden of EPP and multiple preclinical models highlighting the potential benefits of bitopertin, DISC-0974, and DISC-3405 in existing and new indications. The collection of data supports Disc's continued advancement of all three clinical candidates and provides evidence for expansion opportunities in new indications.
Neutral
GlobeNewsWire
2 months ago
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive updated results from a Phase 1b trial of DISC-0974 in patients with myelofibrosis (MF) and anemia. The data, presented in an oral session at the 2024 American Society of Hematology (ASH) annual meeting in San Diego, CA, demonstrated that treatment with DISC-0974 results in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types.
Neutral
GlobeNewsWire
3 months ago
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences:
Charts implemented using Lightweight Charts™